Toronto, Ontario, Canada, February 2026 – Martin Arès has joined Apotex Corp. as President, Canada & Rest of World (ex-US & Latin America), taking on leadership of the company’s Canadian business and supporting expansion across global markets outside the United States and Latin America.
Under Apotex’s CEO leadership, Martin will lead the Canadian business across Generics, Branded products, Biosimilars, and CanPrev Consumer Health. He will also support the growth of Rest of World markets and the international expansion of CanPrev.
Sharing his excitement about the opportunity, Martin highlighted Apotex’s strong commercial heritage and customer mindset, noting that for more than 50 years, the company has been a trusted partner to healthcare providers, payers, and patients, with a mission centered on expanding access to affordable and innovative medicines globally. He emphasized that Apotex’s comprehensive portfolio, strong pipeline, and continued investment in innovation and capabilities create significant opportunity to make a meaningful difference in global health.
Prior to joining Apotex, Martin served as Chief Executive Officer at Pharmascience, where he led a $1 billion specialty-generic business with more than 1,550 employees. During his tenure, he oversaw significant annual investments in R&D, strengthened manufacturing efficiency across oral solid and sterile injectable facilities, and implemented a forward-looking corporate strategy to enhance long-term profitability through high-value pipeline transformation.
Earlier, Martin held multiple senior leadership roles at Sandoz, including Vice President, Biosimilars and Specialty – US Market, where he was a member of the Global Biosimilar Executive Committee with full P&L responsibility. He also led US Solid Oral Generics and previously served in Canada as Vice President for Biosimilars & Generics and Generics & Specialty, managing large portfolios and driving commercial excellence.
His career also includes executive roles at Sanofi, where he led the Diabetes & Cardiovascular Franchise in Canada; Bristol-Myers Squibb; Analogic; and a 14-year tenure at Roche, where he held several international leadership positions including Country Head for the Scandinavian market and Global Head of Product Management & Country Support for the Diabetes Care portfolio.
With deep expertise spanning global strategy, biosimilars, specialty generics, manufacturing, and commercial leadership, Martin Arès brings a strong track record of delivering growth, operational excellence, and sustainable value creation across complex healthcare markets.
About Apotex Corp.
Apotex Corp. is the United States affiliate of Apotex Inc., a global health company dedicated to improving everyday access to affordable and innovative medicines and health products. Its portfolio includes more than 550 generic, biosimilar, and innovative medicines, along with more than 225 natural health products, serving patients worldwide.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
